$NKTR
Nektar Therapeutics Stock $nktr

$nktr Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000090670922000010 Filed on May 06, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$24.82M	$23.65M
YoY Change	4.97%	-53.24%
Cost Of Revenue	$5.315M	$5.756M
YoY Change	-7.66%	51.04%
Gross Profit	$19.51M	$17.89M
YoY Change	9.03%	-61.74%
Gross Profit Margin	78.59%	75.66%
Selling, General & Admin	$27.34M	$31.70M
YoY Change	-13.76%	20.99%
% of Gross Profit	140.15%	177.18%
Research & Development	$107.3M	$95.60M
YoY Change	12.18%	-12.28%
% of Gross Profit	549.82%	534.37%
Depreciation & Amortization	$3.730M	$3.500M
YoY Change	6.57%	-22.22%
% of Gross Profit	19.12%	19.56%
Operating Expenses	$107.3M	$95.60M
YoY Change	12.18%	-12.28%
Operating Profit	-$116.6M	-$109.4M
YoY Change	6.55%	-18.14%
Interest Expense	$26.29M	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	$26.29M	-$13.48M
YoY Change	-295.01%	179.73%
Pretax Income	-$90.27M	-$122.9M
YoY Change	-26.54%	-11.25%
Income Tax	$126.0K	$92.00K
% Of Pretax Income
Net Earnings	-$90.39M	-$123.0M
YoY Change	-26.49%	-11.31%
Net Earnings / Revenue	-364.16%	-520.01%
Basic Earnings Per Share	-$0.49	-$0.68
Diluted Earnings Per Share	-$0.49	-$0.68
COMMON SHARES
Basic Shares Outstanding	185.8M shares	181.4M shares
Diluted Shares Outstanding	185.8M shares	181.4M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$667.0M	$1.037B
YoY Change	-35.7%	-22.93%
Cash & Equivalents	$67.99M	$150.2M
Short-Term Investments	$599.0M	$887.2M
Other Short-Term Assets	$20.83M	$15.77M
YoY Change	32.08%	14.19%
Inventory	$15.38M	$16.81M
Prepaid Expenses
Receivables	$30.22M	$29.16M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$733.5M	$1.099B
YoY Change	-33.26%	-23.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$60.98M	$58.51M
YoY Change	4.22%	-6.09%
Goodwill	$76.50M	$76.50M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$37.36M	$96.10M
YoY Change	-61.12%	-48.31%
Other Assets	$1.521M	$1.435M
YoY Change	5.99%
Total Long-Term Assets	$290.7M	$357.5M
YoY Change	-18.7%	-22.04%
TOTAL ASSETS
Total Short-Term Assets	$733.5M	$1.099B
Total Long-Term Assets	$290.7M	$357.5M
Total Assets	$1.024B	$1.457B
YoY Change	-29.69%	-22.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.62M	$22.43M
YoY Change	-43.76%	2.96%
Accrued Expenses	$92.66M	$101.2M
YoY Change	-8.43%	4.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$105.3M	$123.6M
YoY Change	-14.84%	-67.25%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.704M	$4.130M
YoY Change	-34.53%	-98.07%
Total Long-Term Liabilities	$2.704M	$4.130M
YoY Change	-34.53%	-98.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$105.3M	$123.6M
Total Long-Term Liabilities	$2.704M	$4.130M
Total Liabilities	$416.2M	$462.1M
YoY Change	-9.92%	-21.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.923B	-$2.432B
YoY Change	20.2%	21.4%
Common Stock	$3.538B	$3.430B
YoY Change	3.15%	3.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$607.9M	$994.5M
YoY Change
Total Liabilities & Shareholders Equity	$1.024B	$1.457B
YoY Change	-29.69%	-22.85%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$90.39M	-$123.0M
YoY Change	-26.49%	-11.31%
Depreciation, Depletion And Amortization	$3.730M	$3.500M
YoY Change	6.57%	-22.22%
Cash From Operating Activities	-$88.42M	-$77.09M
YoY Change	14.71%	-1.27%
INVESTING ACTIVITIES
Capital Expenditures	$4.203M	$2.876M
YoY Change	46.14%	219.56%
Acquisitions
YoY Change
Other Investing Activities	$134.5M	$13.30M
YoY Change	911.14%	-93.31%
Cash From Investing Activities	$130.3M	$10.46M
YoY Change	1145.73%	-94.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$938.0K	$17.86M
YoY Change	-94.75%	61.2%
NET CHANGE
Cash From Operating Activities	-$88.42M	-$77.09M
Cash From Investing Activities	$130.3M	$10.46M
Cash From Financing Activities	$938.0K	$17.86M
Net Change In Cash	$42.78M	-$48.79M
YoY Change	-187.67%	-137.34%
FREE CASH FLOW
Cash From Operating Activities	-$88.42M	-$77.09M
Capital Expenditures	$4.203M	$2.876M
Free Cash Flow	-$92.63M	-$79.96M
YoY Change	15.84%	1.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000906709
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	0-24006
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	NEKTAR THERAPEUTICS
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3134940
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 Mission Bay Boulevard South
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94158
CY2022Q1	dei	City Area Code CityAreaCode	415
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	482-5300
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2022Q1	dei	Trading Symbol TradingSymbol	NKTR
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	186274156	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67993000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25218000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	599032000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	708737000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30220000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22492000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	15379000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	15801000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	20831000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	23333000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	733455000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	795581000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	37363000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	64828000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60980000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60510000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	114296000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	117025000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	76501000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	76501000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1521000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2744000	USD
CY2022Q1	us-gaap	Assets Assets	1024116000	USD
CY2021Q4	us-gaap	Assets Assets	1117189000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	12617000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9747000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22653000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15735000	USD
CY2022Q1	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	33403000	USD
CY2021Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	26809000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17011000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	15468000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	19597000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	17441000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	105281000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85200000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	122638000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	125736000	USD
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	27726000	USD
CY2022Q1	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	185604000	USD
CY2021Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	195427000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2704000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3592000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	416227000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	437681000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	185468000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	186274000	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	19000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	19000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3537790000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3516641000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6532000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4157000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2923388000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2832995000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	607889000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	679508000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1024116000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1117189000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24822000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23647000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5315000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5756000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	107253000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	95604000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27339000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31679000	USD
CY2022Q1	us-gaap	Restructuring Charges RestructuringCharges	1475000	USD
CY2021Q1	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	141382000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	133039000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-116560000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-109392000	USD
CY2022Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	33427000	USD
CY2021Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-1599000	USD
CY2022Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	7529000	USD
CY2021Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	13296000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	395000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1412000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26293000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13483000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-90267000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-122875000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	126000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	92000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-90393000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-122967000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	185848000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	185848000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	181370000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	181370000	shares
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	188000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20961000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-90393000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-122967000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2091000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-766000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-284000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-60000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2375000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-826000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-92768000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-123793000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1077295000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	17106000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23898000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-123793000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	994506000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	679508000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1276000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-92768000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	607889000	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-90393000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-122967000	USD
CY2022Q1	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	17561000	USD
CY2021Q1	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	18798000	USD
CY2022Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	7529000	USD
CY2021Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	13296000	USD
CY2022Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	33427000	USD
CY2021Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-1599000	USD
CY2022Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	4951000	USD
CY2021Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2248000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20961000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23898000	USD
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3730000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3543000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2345000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7728000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9733000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-422000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1516000	USD
CY2022Q1	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-1787000	USD
CY2021Q1	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-1541000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2864000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-6183000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2998000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	779000	USD
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	6918000	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	8981000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	7249000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-7950000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-88424000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-77085000	USD
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	93493000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	295314000	USD
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	227974000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	303612000	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5036000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4203000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2876000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	130278000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10458000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	188000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	17106000	USD
CY2022Q1	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	750000	USD
CY2021Q1	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	750000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	938000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17856000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-17000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-20000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	42775000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-48791000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25218000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198955000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67993000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150164000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1057000	USD
CY2022Q1	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	704400000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div>
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of March 31, 2022 and December 31, 2021, our accounts receivable includes $26.9 million and $21.4 million, respectively, for unbilled net expense reimbursements from BMS. The remaining accounts receivable relate primarily to product sales. We generally do not require collateral from our customers. We perform a regular review of our customers’ credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three months ended March 31, 2022 and 2021. We have not recorded a reserve for credit losses at March 31, 2022 or December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div>For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic or other factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer’s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67993000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25218000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	599032000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	708737000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	37363000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	64828000	USD
CY2022Q1	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	704388000	USD
CY2021Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	798783000	USD
CY2022Q1	nktr	Debt Investment Maximum Maturity Period DebtInvestmentMaximumMaturityPeriod	P2Y
CY2022Q1	nktr	Debt Investment Maturity Term DebtInvestmentMaturityTerm	P1Y
CY2022Q1	us-gaap	Cash Cash	11922000	USD
CY2021Q4	us-gaap	Cash Cash	1250000	USD
CY2022Q1	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	704388000	USD
CY2021Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	798783000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	700000	USD
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2084000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3166000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9420000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9342000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3875000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3293000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	15379000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	15801000	USD
CY2022Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	0	USD
	nktr	Royalty Monetization Proceeds RoyaltyMonetizationProceeds	274000000	USD
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	-351012000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	251802000	USD
	nktr	Partial Repayment Of Royalty Sale Proceeds PartialRepaymentOfRoyaltySaleProceeds	10000000	USD
	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sale Of Future Royalties Gross GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross	23522000	USD
CY2022Q1	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	188312000	USD
CY2022Q1	nktr	Liabilities On Sale Of Future Royalties Unamortized Transaction Costs LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts	2708000	USD
CY2022Q1	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	185604000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20961000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23898000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	22000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	121000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.61
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.82
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22338000	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19393000	shares

Files In Submission

Name	View Source	Status
0000906709-22-000010-index-headers.html	Edgar Link	pending
0000906709-22-000010-index.html	Edgar Link	pending
0000906709-22-000010.txt	Edgar Link	pending
0000906709-22-000010-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nktr-20220331.htm	Edgar Link	pending
nktr-20220331.xsd	Edgar Link	pending
nktr-20220331_cal.xml	Edgar Link	unprocessable
nktr-20220331_def.xml	Edgar Link	unprocessable
nktr-20220331_htm.xml	Edgar Link	completed
nktr-20220331_lab.xml	Edgar Link	unprocessable
nktr-20220331_pre.xml	Edgar Link	unprocessable
nktr2022-03x31xexx311.htm	Edgar Link	pending
nktr2022-03x31xexx312.htm	Edgar Link	pending
nktr2022-03x31xexx321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NKTR
Nektar Therapeutics Stock $nktr

2022 Q1 Form 10-Q Financial Statement

#000090670922000010 Filed on May 06, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR Nektar Therapeutics Stock $nktr

2022 Q1 Form 10-Q Financial Statement

#000090670922000010 Filed on May 06, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR
Nektar Therapeutics Stock $nktr